Literature DB >> 2413616

Infection of human T-lymphotropic virus type-I (HTLV-I)-bearing MT-4 cells with HTLV-III (AIDS virus): chronological studies of early events.

S Harada, Y Koyanagi, N Yamamoto.   

Abstract

Early events in the infection of the human T-lymphotropic virus type-I (HTLV-I)-positive MT-4 cell line by the acquired immune deficiency syndrome (AIDS) retrovirus HTLV-III were investigated. The virus was adsorbed completely to the cells within 60 min incubation after inoculation of the virus. Then, infected MT-4 cells started to produce the HTLV-III-specific antigens between 12 and 24 hr postinfection. Synthesis of the viral antigens consisting of 120K, 46K, 24K, and 17K polypeptides was suppressed by the treatment of the virus-infected MT-4 cells with cytosine arabinoside (Ara-C) or by the treatment of the virus with anti-HTLV-III-positive sera. The progeny of the virus released from the infected MT-4 cells was titrated by a newly developed plaque-forming assay method and reverse transcriptase activity. The maximum activity of HTLV-III (3 X 10(5) PFU/ml) was observed on Days 4 and 5 p.i. Most of the viral activities in this preparation were ascribed to HTLV-III, and not to HTLV-I. No phenotypic mixing between HTLV-III and HTLV-I was discerned, although MT-4 cells were HTLV-I-producer cell line. Thus, HTLV-III-infected MT-4 cells are thought to be useful in further study of the interaction between host cells and the virus, and appear to be a good viral source for the analysis of the virus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413616     DOI: 10.1016/0042-6822(85)90010-8

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  23 in total

1.  A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity.

Authors:  Kozi Ichiyama; Sei Yokoyama-Kumakura; Yuetsu Tanaka; Reiko Tanaka; Kunitaka Hirose; Kenji Bannai; Takeo Edamatsu; Mikiro Yanaka; Yoshiaki Niitani; Naoko Miyano-Kurosaki; Hiroshi Takaku; Yoshio Koyanagi; Naoki Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

2.  Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4.

Authors:  R Kikukawa; Y Koyanagi; S Harada; N Kobayashi; M Hatanaka; N Yamamoto
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

3.  Entry of human immunodeficiency virus (HIV) into MT-2, human T cell leukemia virus carrier cell line.

Authors:  T Goto; S Harada; N Yamamoto; M Nakai
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

4.  In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.

Authors:  Q Gao; Z X Gu; M A Parniak; X G Li; M A Wainberg
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  Effect of retinoic acid on the replication of human immunodeficiency virus in HTLV-I-positive MT-4 cells.

Authors:  H Nakashima; S Harada; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

6.  Plaque staining assay for non- or weakly cytotoxic human immunodeficiency virus.

Authors:  T Matsui; H Nakashima; H Yoshiyama; N Kobayashi; N Yamamoto
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

7.  Purification and characterization of an avian myeloblastosis and human immunodeficiency virus reverse transcriptase inhibitor, sulfated polysaccharides extracted from sea algae.

Authors:  H Nakashima; Y Kido; N Kobayashi; Y Motoki; M Neushul; N Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

8.  Antibody that inhibits human immunodeficiency virus reverse transcriptase and association with inability to isolate virus.

Authors:  K Sano; M H Lee; F Morales; P Nishanian; J Fahey; R Detels; D T Imagawa
Journal:  J Clin Microbiol       Date:  1987-12       Impact factor: 5.948

9.  Antiretroviral activity in a marine red alga: reverse transcriptase inhibition by an aqueous extract of Schizymenia pacifica.

Authors:  H Nakashima; Y Kido; N Kobayashi; Y Motoki; M Neushul; N Yamamoto
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

10.  Evaluation of anti-human immunodeficiency virus effect of recombinant CD4-immunoglobulin in vitro: a good candidate for AIDS treatment.

Authors:  I H Chowdhury; Y Koyanagi; K Takamatsu; O Yoshida; S Kobayashi; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.